Journal article
New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer
- Abstract:
- BACKGROUND: The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses. METHODS: In total, 2298 women (≥45 years, invasive ductal carcinoma ≤3.5 cm, cN0-N1) were randomised. We investigated the impact of tumour size, grade, ER, PgR, HER2 and lymph node status on local recurrence-free survival, and of local recurrence on distant relapse and mortality. We analysed the predictive factors for recommending supplemental EBRT after TARGIT-IORT as part of the risk-adapted approach, using regression modelling. Non-breast cancer mortality was compared between TARGIT-IORT plus EBRT vs. EBRT. RESULTS: Local recurrence-free survival was no different between TARGIT-IORT and EBRT, in every tumour subgroup. Unlike in the EBRT arm, local recurrence in the TARGIT-IORT arm was not a predictor of a higher risk of distant relapse or death. Our new predictive tool for recommending supplemental EBRT after TARGIT-IORT is at https://targit.org.uk/addrt . Non-breast cancer mortality was significantly lower in the TARGIT-IORT arm, even when patients received supplemental EBRT, HR 0.38 (95% CI 0.17-0.88) P = 0.0091. CONCLUSION: TARGIT-IORT is as effective as EBRT in all subgroups. Local recurrence after TARGIT-IORT, unlike after EBRT, has a good prognosis. TARGIT-IORT might have a beneficial abscopal effect. TRIAL REGISTRATION: ISRCTN34086741 (21/7/2004), NCT00983684 (24/9/2009)
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 588.1KB, Terms of use)
-
- Publisher copy:
- 10.1038/s41416-021-01440-8
- Publication website:
- https://discovery.dundee.ac.uk/files/58916484/s41416_021_01440_8.pdf
Authors
+ Bundesministerium für Bildung und Forschung
More from this funder
- Funder identifier:
- 10.13039/501100002347
- Grant:
- FKZ 01ZP0508
+ Federal Ministry of Health, Germany | Bundeszentrale für gesundheitliche Aufklärung
More from this funder
- Funder identifier:
- 10.13039/501100003108
- Grant:
- FKZ 01ZP0508
+ DH | NIHR | Health Technology Assessment Programme
More from this funder
- Funder identifier:
- 10.13039/501100000664
- Grant:
- HTA 10/04/07
- HTA 07/60/49
- HTA 14/49/13
- HTA 07/60/49
- HTA 10/04/07
- HTA 14/49/13
- HTA 07/60/49
- HTA 10/04/07
- HTA 14/49/13
- HTA 10/04/07
- HTA 14/49/13
- HTA 10/04/07
- HTA 07/60/49
- HTA 10/04/07
- HTA 14/49/13
- HTA 07/60/49
- HTA 14/49/13
- HTA 07/60/49
- HTA 10/04/07
- HTA 14/49/13
+ Department of Health | National Health and Medical Research Council
More from this funder
- Funder identifier:
- 10.13039/501100000925
- Publisher:
- Springer Nature [academic journals on nature.com]
- Journal:
- British Journal of Cancer More from this journal
- Volume:
- 125
- Issue:
- 3
- Pages:
- 380-389
- Publication date:
- 2021-05-25
- DOI:
- EISSN:
-
1532-1827
- ISSN:
-
0007-0920
- Language:
-
English
- Keywords:
- Pubs id:
-
1179436
- Local pid:
-
pubs:1179436
- Source identifiers:
-
W3164978296
- Deposit date:
-
2026-03-24
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2021
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record